Our client is committed to translating the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. To date, they have obtained over 1100 million RMB fundings from several well-known investors. In addition, investigational New Drug (IND) application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA).
They are focusing on developing novel therapies to cure blood inherited diseases and fulfill the clinical unmet needs during the hematopoietic stem cell transplantation via using cutting-edge gene-editing technologies and innovative HSC-related systems. They are looking for an experienced and passionate R&D Associate Director to aid in advancing their platform.
This is a Full-Time position in Beijing, China.
They are focusing on developing novel therapies to cure blood inherited diseases and fulfill the clinical unmet needs during the hematopoietic stem cell transplantation via using cutting-edge gene-editing technologies and innovative HSC-related systems. They are looking for an experienced and passionate R&D Associate Director to aid in advancing their platform.
This is a Full-Time position in Beijing, China.
Responsibilities
|
Requirements
|